|
| Year, acronym | Disease | Cell source | Route of delivery | Primary outcome | Reference |
|
| 2004 | AMI () | MSC, 18 days after AMI (9 × 109) | Intracoronary | 6 months after therapy
↑ LVEF () | Chen et al. [8] |
|
| 2004, BOOST | AMI () | BMMC, 5 days after AMI | Intracoronary | 6 months after therapy
↑ LVEF () | Wollert et al. [17] |
|
| 2005 | AMI () | CD133+ cells, 12 days after AMI
(15 × 106) | Intracoronary | 4 months after therapy
↑ LVEF () | Bartunek et al. [18] |
|
| 2005, MYSTAR | AMI () | BMSC, early group, 3–6 weeks, and late group, 3-4 months after AMI
(2 × 108 intramyocardial; 1,3 × 109 intracoronary) | Intramyocardial/intracoronary | 3 months after therapy
↑ LVEF (, early group)
↓ infarct size (, early group) | Gyöngyösi et al. [19] |
|
| 2006 | AMI () | BMSC, 1 day after AMI
(2 × 108) | Intracoronary | 4 months after therapy
↔ LVEF ()
↓ infarct size () | Janssens et al. [20] |
|
| 2008, MAGIC | Left ventricular dysfunction/AMI | Autologous skeletal myoblasts (4–8 × 108) | Intramyocardial | 6 months after therapy
↔ LVEF ()
↔ LVEDV ()
↔ LVESV () | Menasché et al. [12] |
|
| 2012 (meta-analysis) | AMI or ischemic heart disease
(50 studies; ) | BMDC | Intramyocardial or
intracoronary | ↑ LVEF ()
↓ infarct size ()
↓ LVESV ()
↓ LVEDV () | Jeevanantham et al. [21] |
|
| 2012, POSEIDON | Ischemic cardiomyopathy () | MSC
(2 × 107, 1 × 108, 2 × 108) | Transendocardial | 13 months after therapy
↓ infarct size ()
↔ LVEF () | Hare et al. [22] |
|
| 2013, C-CURE | CHF/recent AMI
() | Cardiopoietic stem cells
(6–12 × 108) | Intramyocardial | 6 months after therapy
↑ LVEF ()
↓ LVESV () | Bartunek et al. [23] |
|
| 2014, PRECISE | Ischemic cardiomyopathy/CHF
() | ADSC (42 × 106) | Transendocardial | 6 months after therapy
↔ infarct size ()
↔ LVEF () | Perin et al. [9] |
|
| 2014 | Ischemic heart failure
() | BMMC (8.4 × 108) | Intramyocardial | 1 year after therapy
↔ LVEF ()
↓ infarct size () |
Pätilä et al. [24] |
|
